NAGESHWARA V. DASARI to Maximum Tolerated Dose
This is a "connection" page, showing publications NAGESHWARA V. DASARI has written about Maximum Tolerated Dose.
Connection Strength
0.265
-
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors. Invest New Drugs. 2023 Jun; 41(3):421-430.
Score: 0.168
-
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs. 2013 Feb; 31(1):115-25.
Score: 0.078
-
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. Invest New Drugs. 2013 Apr; 31(2):345-54.
Score: 0.020